Collegium Pharmaceutical, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021 at 04:01 pm EDT
Share
Collegium Pharmaceutical, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating income was USD 16.409 million compared to USD 16.549 million a year ago. Net income was USD 72.843 million compared to USD 8.058 million a year ago. Basic earnings per share from continuing operations was USD 2.06 compared to USD 0.23 a year ago. Diluted earnings per share from continuing operations was USD 1.79 compared to USD 0.23 a year ago. For the half year, operating income was USD 37.601 million compared to USD 21.610 million a year ago. Net income was USD 88.505 million compared to USD 8.508 million a year ago. Basic earnings per share from continuing operations was USD 2.52 compared to USD 0.25 a year ago. Diluted earnings per share from continuing operations was USD 2.2 compared to USD 0.24 a year ago.
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
COLLEGIUM PHARMACEUTICAL, INC. 
